Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 4/20 | 0.38 |
| ▸ | MTOR | P42345 | 4/20 | 0.38 |
| ▸ | PLK4 | O00444 | 13/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 7/20 | 0.38 |
| ▸ | PDE1A | P54750 | 2/20 | 0.37 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.37 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.36 |
| ▸ | PAK4 | O96013 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2314682 | 0.84 | PIK3CA (0.44) | PIK3CAMTORPIK3CG | |
| SCHEMBL2314694 | 0.84 | PIK3CA (0.44) | PIK3CAMTORPIK3CG | |
| SCHEMBL2312913 | 0.79 | GGPS1 (0.41) | PLK4HTT | |
| SCHEMBL30476568 | 0.79 | GGPS1 (0.41) | PLK4HTT | |
| SCHEMBL2314422 | 0.79 | PIK3CA (0.43) | PIK3CAMTORPIK3CGHTT | |
| SCHEMBL21017199 | 0.74 | TLR9 (0.38) | PIK3CAMTORPIK3CGHTT | |
| SCHEMBL2316755 | 0.74 | AHR (0.43) | NTRK1HTT | |
| SCHEMBL2317411 | 0.71 | PIK3CA (0.44) | PIK3CAMTORPIK3CG | |
| SCHEMBL13253979 | 0.71 | PIK3CA (0.44) | PIK3CAMTORPIK3CG | |
| SCHEMBL13253978 | 0.71 | PIK3CA (0.44) | PIK3CAMTORPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170239296-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | NOVARTIS AG (CH) | 2017-08-24 | — | — | US | disclosed |
| US-20170239296-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | NOVARTIS AG (CH) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239296-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | CD47, HCLS1, CD74 | PIK3CA 1299/4885MTOR 1140/4885PLK4 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.